Sagimet Biosciences (SGMT) Insider Jarrett Buys 39,567 Shares

Insider Buying and Selling at Sagimet Biosciences Inc.

Jennifer Jarrett picked up 39,567 shares of Sagimet Biosciences Inc. (NasdaqGM: SGMT) on June 12, 2026. This transaction aligns with earlier disclosures from the same date showing fellow insiders George Kemble and Anne Phillips also acquiring matching blocks of 39,567 shares each. These insider transactions give market watchers a closer look at how leaders inside the organization manage their personal holdings as the firm advances its clinical programs.

Sagimet Biosciences Stock Performance and Price Levels

Shares of Sagimet Biosciences changed hands around $6.47 recently. The stock moves within a 52-week range spanning from a low of $4.50 up to a high of $11.45. Its 50-day moving average rests at $9.33, while the 200-day moving average sits near $7.02. With a market capitalization of roughly $671.3 million, the equity continues to experience routine shifts as investors weigh the firm's developmental pipeline.

Recent Analyst Ratings and Coverage Updates

Wall Street firms maintain an active dialogue regarding the biotech firm's prospects. On October 5, 2026, HC Wainwright & Co. reiterated a buy rating alongside a $29.00 price target. Guggenheim maintained a buy rating on October 2, 2026, while lifting its target to $26.00. Earlier on October 1, 2026, Oppenheimer kept an outperform rating with a $38.00 target, and Citizens held a market outperform rating while adjusting its target to $27.00. Looking back to September, Barclays upgraded the stock to overweight with an $18.00 target on September 9, 2026, and Cantor Fitzgerald initiated coverage with an overweight rating and a $10.71 target on the same day. Overall, analysts hold a strong buy consensus backed by a mean price target of $29.60 across ten opinions.

Behind the Biotech Pipeline

Headquartered in San Mateo, California, Sagimet Biosciences focuses on developing novel therapeutics known as fatty acid synthase inhibitors. These treatments target metabolic and fibrotic pathways, including metabolic dysfunction-associated steatohepatitis and specific forms of acne and cancer. The organization employs a small team of 16 people dedicated to advancing candidates like its lead oral pill, Denifanstat, through clinical evaluations.

What to Watch Next for SGMT

Participants will track upcoming corporate updates and regulatory milestones for any shifts in momentum. The company scheduled its next earnings report for November 12, 2026, which will provide additional financial data regarding its ongoing research expenditures and cash runway. These scheduled disclosures offer a clearer window into the operational progress behind the developer's pipeline.